Vincerx Pharma, Inc.
VINC
$0.05
-$0.005-9.09%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.74% | 73.52% | 10.75% | -5.22% | -35.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.42% | 16.14% | -18.90% | -38.92% | -51.47% |
| Operating Income | 55.42% | -16.14% | 18.90% | 38.92% | 51.47% |
| Income Before Tax | 59.77% | -61.49% | 12.92% | 84.35% | 15.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.77% | -61.49% | 12.92% | 84.35% | 15.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.77% | -61.49% | 12.92% | 84.35% | 15.16% |
| EBIT | 55.42% | -16.14% | 18.90% | 38.92% | 51.47% |
| EBITDA | 55.51% | -16.16% | 18.92% | 38.96% | 51.51% |
| EPS Basic | 87.81% | 22.95% | 40.80% | 88.85% | 17.16% |
| Normalized Basic EPS | 87.81% | 46.08% | 40.80% | 88.85% | 17.16% |
| EPS Diluted | 87.81% | 22.95% | 40.80% | 88.85% | 17.16% |
| Normalized Diluted EPS | 87.81% | 46.08% | 40.80% | 88.85% | 17.16% |
| Average Basic Shares Outstanding | 229.95% | 109.60% | 47.08% | 40.41% | 2.42% |
| Average Diluted Shares Outstanding | 229.95% | 109.60% | 47.08% | 40.41% | 2.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |